Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss ... Aligos Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.63 million ...

Keros Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry ... Aligos Therapeutics, Inc. (ALGS), another stock in the same industry, has yet to report results ...

LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently being evaluated ... a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently ... a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses ...

Get Instant Summarized Text (Gist) A genetic analysis of Greenlanders identified unique genetic variants linked to their isolated communities and adaptation to the harsh environment. The study ...

More than 80% of all genetic research is conducted in individuals of European ancestry 1, raising concerns that Indigenous people and other under-represented groups might not benefit from the ...